Dexamethasone eluting biodegradable polymeric matrix coated stent for intravascular drug delivery

Chemical Engineering Research and Design

Volumn 88, Issue 11, 2010, Pages 1479-1484

  Raval, Ankur ^a   Parikh, Jigisha ^a   Engineer, Chhaya ^b  

^a SARDAR VALLABHBHAI NATIONAL INSTITUTE OF TECHNOLOGY   (India)

^b Sahajanand Medical Technologies Pvt Ltd   (India)

Author keywords

Biodegradable polymers; Dexamethasone; Drug release kinetics; Stent

Indexed keywords

ADVERSE EFFECT; ANTI-INFLAMMATORIES; ANTI-PROLIFERATIVE; CAPROLACTONE; CARDIOVASCULAR STENTS; CO-CR ALLOYS; COATING PARAMETERS; CONTROLLED DRUG RELEASE; CORONARY ARTERY BYPASS GRAFTING; DEXAMETHASONES; DRUG CONCENTRATION; DRUG ELUTION; DRUG RELEASE KINETICS; DRUG-ELUTING STENTS; IN-VITRO; INTRAVASCULAR; METALLIC STENTS; MULTIPLE LAYERS; OPTIMIZED USE; PHARMACEUTICAL AGENTS; POLY VINYL PYRROLIDONE; POLY-L-LACTIDE; POLYMERIC MATRICES; RELEASE KINETICS; SEM; SMOOTH SURFACE; STENT; TARGET SITES; TARGETED DRUG DELIVERY;

BIODEGRADABLE POLYMERS; CHROMIUM; CHROMIUM ALLOYS; DRUG PRODUCTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; OPTIMIZATION; PLASTIC COATINGS; POLYMER BLENDS; SCANNING ELECTRON MICROSCOPY;

CONTROLLED DRUG DELIVERY;

EID: 78149412576     PISSN: 02638762     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cherd.2010.03.007     Document Type: Article

References (27)

1. Cai Q., Bei J., Wang S. Relationship among drug delivery behavior, degradation behavior and morphology of copolylactones derived from glycolide, l-lactide and e{open}-caprolactone. Polymer Adv Technol 2002, 13:105-111.
2. Colombo A., Drzewiecki J., Banning A., Grube E., Hauptmann K., Silber S., Dudek D., Fort S., Schiele F., Zmudka K., Guagliumi G., Russell M.E. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based Paclitaxel-eluting stents for coronary artery lesions. Circulation 2003, 108:788-794.
3. Dickers K.J., Milroy G.E., Huatan H., Cameron R.E. The Use of Biodegradable Polymers in Drug Delivery Systems to Provide Pre-Programmed Release 2002, Cambridge Centre for Medical Materials, Department of Materials Science and Metallurgy, University of Cambridge; The Drug Delivery Companies Report Autumn/Winter.
4. Finn A.V., Nakazawa G., Joner M., Kolodgie F.D., Mont E.K., Gold H.K., Virmani R. Vascular responses to drug eluting stents importance of delayed healing. Arterioscler Thromb Vasc Biol 2007, 27:1500-1510.
5. Frederick G.P., Welt Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002, 22:1769-1776.
6. Gaspardone A., Versaci F. Coronary stenting and inflammation. Am J Cardiol 2005, 96:65-70.
7. Hickey T., Kreutzer D., Burgess D.J., Moussy F. In vivo evaluation of a dexamethasone/PLGA microsphere system designed to suppress the inflammatory tissue response to implantable medical devices. J Biomed Mater Res 2002, 61:180-187.
8. Hickey T., Kreutzer D., Burgess D.J., Moussy F. Dexamethasone/PLGA microspheres for continuous delivery of an anti-inflammatory drug for implantable medical devices. Biomaterials 2002, 23:1649-1656.
9. Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension. J Pharm Sci 1961, 50:874-875.
10. Hoffmann R., Langenberg R., Radke P., Franke A., Blindt R., Ortlepp J., et al. Evaluation of a high-dose dexamethasone-eluting stent. Am J Cardiol 2004, 15(94):193-195.
11. Hoffmann R., Mintz G.S. Coronary in-stent restenosis-predictors, treatment and prevention. Eur Heart J 2000, 21:1739-1749.
12. Kamath K., Barry J., Miller K. The Taxus™ drug-eluting stent: a new paradigm in controlled drug delivery. Adv Drug Deliv Rev 2006, 58:412-436.
13. Kawamura M., Hatanaka K., Saito M., Ogino M., Ono T., Ogino K., Matsuo S., Harada Y. Are the anti-inflammatory effects of dexamethasone responsible for inhibition of the induction of enzymes involved in prostanoid formation in rat carrageenin induced pleurisy?. Eur J Pharmacol 2000, 400:127-135.
14. Korsmeyer R.W., Gurny R., Doelker E.M., Buri P., Peppas N.A. Mechanism of solute release from porous hydrophilic polymers. Int J Pharm 1983, 15:25-35.
15. Leon M.B., Abizaid A., Moses J.W. The CYPHER™ Stent: A New Gold Standard in the Treatment of Coronary Artery Disease 2003, The Cardiovascular Research Foundation, New York, NY, p. 90.
16. Liu X., Hanet C., Vandormael V., Huang Y., De Scheerder I. Study of anti-restenosis with the BiodivYsio dexamethasone eluting stent (STRIDE)-a multicenter trial. Eur Heart J 2002, 23:265.
17. Mintz G.S., Hoffmann R., Mehran R., Pichard A.D., Kent K.M., Satler L.F., Popma J.J., Leon M.B. In-stent restenosis: the Washington Hospital Center experience. Am J Cardiol 1998, 81(7):7E-13E.
18. Moussa I., Leon M.B., Baim D.S., O'Neill W.W., Popma J.J., Buchbinder M., Midwall J., Simonton C.A., Keim E., Wang P., Kuntz R.E., Moses J.W. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx velocity balloon expandable stent in the treatment of patients with de novo coronary artery lesions) sub study. Circulation 2004, 109:2273-2278.
19. Otsuka Y., Chronos N., Apkarian R., Robinson K. Scanning electron microscopic analysis of defects in polymer coatings of three commercially available stents: comparison of BiodivYsio, taxus and cypher stents. J Invasive Cardiol 2007, 19(2):71-76.
20. Peppas N.A. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv 1985, 60:110-111.
21. Radke P., Weber C., Kaiser A., Schober A., Hoffmann R. Dexamethasone and restenosis after coronary stent implantation: new indication for an old drug?. Curr Pharm Des 2004, 10(4):349-355.
22. Robinson J.R., Lee V.H.L. Controlled Drug Delivery: Fundamentals and Applications 1987, Marcel Dekker Inc., New York, pp. 167-168. 2nd ed.
23. Valero S.J., Moreno R., Recalde A.S., Galeote G., Calvo L., Viana A., Lopez de Sá E., Sendón J.L. Avoiding restenosis: is there a role for glucocorticoids in the drug-eluting stent era?. Ther Adv Cardiovasc Dis 2008, 2(3):137-146.
24. Villa A.E., Guzman L.A., Chen W., Golomb G., Levy R.J., Topol E.J. Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty. J Clin Invest 1994, 93(3):1243-1249.
25. Virmani R., Guagliumi G., Farb A., Musumeci G., Grieco N., Motta T., Mihalcsik Tespili L.M., Valsecchi O., Kolodgie F. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent should we be cautious?. Circulation 2004, 109:701-705.
26. Windecker S., Juni P. The drug-eluting stent saga. Circulation 2009, 119:653-656.
27. Zahirul M., Khan I. Dissolution testing for sustained or controlled release oral dosage forms and correlation with in vivo data: challenges and opportunities. Int J Pharm 1996, 140:131-143.